From Schedule I to Schedule III: What Actually Changed

Since the passage of the Controlled Substances Act in 1970, cannabis had been locked into Schedule I — the most restrictive category, reserved for substances deemed to have “no currently accepted medical use” and a “high potential for abuse.” For over 50 years, marijuana sat alongside heroin and LSD in this classification, creating an enormous barrier to legitimate medical research and forcing millions of patients into a legally ambiguous space between state and federal law.

The April 2026 order changes that — but only for specific categories of cannabis. The rescheduling applies to two groups: (1) drug products containing cannabis that have received FDA approval, such as Epidiolex, a CBD-based treatment for severe childhood epilepsy; and (2) marijuana products regulated under state-issued medical marijuana licenses. Notably, recreational or adult-use cannabis remains firmly in Schedule I, and the order explicitly states that it “does not legalize” cannabis in any broader sense.

“This is the most important cannabis policy reform since the creation of the scheduling system itself,” said one health policy researcher at the University of Michigan’s Institute for Healthcare Policy and Innovation. “But it’s also a carefully calibrated half-step. The administration moved on the least politically controversial piece first.”

The Executive Order That Started It All

The rescheduling traces its origins to December 18, 2025, when President Trump signed an executive order titled “Increasing Medical Marijuana and Cannabidiol Research.” The order directed the Attorney General to “take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner.”

The executive order cited multiple factors: the Department of Health and Human Services’ 2023 recommendation to reschedule cannabis; the FDA’s determination that credible scientific evidence supports cannabis for treating pain, chemotherapy-induced nausea, and anorexia related to certain conditions; and the reality that millions of patients across dozens of states were already using medical cannabis under state-authorized programs. The Oval Office signing ceremony notably included Health and Human Services Secretary Robert F. Kennedy Jr., senior administration officials, and veterans advocating for medical cannabis access.

“The executive order represented an acknowledgment from the executive branch that the Schedule I classification had become scientifically indefensible,” said a legal analyst at Foley Hoag LLP who tracks cannabis policy. “HHS already recommended rescheduling in 2023 based on an extensive scientific and medical evaluation. The Trump administration picked up that baton and ran with it.”

The Research Renaissance: Breaking the 50-Year Barrier

Perhaps the most consequential impact of rescheduling lies in its potential to unlock medical research. Under Schedule I, researchers faced an extraordinarily cumbersome process to study cannabis — requiring DEA registration, specialized security protocols, and access to a single federally authorized cultivation facility at the University of Mississippi. The result was a research landscape starved of high-quality data even as millions of Americans consumed cannabis products daily.

“The Schedule I classification effectively imposed a 50-year research moratorium on one of the most widely used therapeutic botanicals in human history,” wrote researchers at The Conversation. Schedule III, while still regulated, treats cannabis more like ketamine, testosterone, or Tylenol with codeine — substances with recognized medical uses and moderate-to-low abuse potential. This means researchers at universities and medical centers can now design and execute clinical trials with dramatically reduced administrative burdens.

Experts expect a surge in research across several critical areas: cannabis for chronic pain management as an alternative to opioids; CBD and THC formulations for PTSD, particularly in veteran populations; cannabinoids for neurological conditions including multiple sclerosis and Parkinson’s disease; and the long-term safety profile of medical cannabis use. The FDA has committed to developing “real-world evidence research models” to systematically study outcomes among the millions of patients already using medical cannabis under state programs.

However, researchers caution that Schedule III placement alone doesn’t solve everything. “It’s a dramatically better framework, but cannabis research will still require institutional review board approval, informed consent protocols, and careful methodology,” noted one clinical researcher. “What changes is that the DEA no longer treats your lab like you’re studying weapons-grade plutonium.”

Tax Reform for Medical Cannabis Businesses

One of the most immediately consequential aspects of rescheduling is the removal of Section 280E of the Internal Revenue Code for state-licensed medical cannabis businesses. Under Schedule I, cannabis companies were prohibited from deducting ordinary business expenses — rent, payroll, utilities — from their federal tax returns, resulting in effective tax rates that could exceed 70% or even 90%.

With Schedule III classification, medical cannabis businesses are now free from 280E’s grip. This tax relief is expected to improve profitability, enable reinvestment in product quality and safety testing, and potentially lower prices for patients. “The 280E burden was strangling legal medical cannabis operators while the illicit market paid no taxes at all,” explained one industry analyst. “Removing it for medical operators is both economically sensible and pro-patient.”

Adult-use cannabis businesses, however, remain fully subject to 280E. This creates a sharp regulatory cliff between medical and recreational operations, even in states where the same facility may serve both markets. “The two-tier system the DOJ has created will force some complex business decisions,” said a tax attorney at Gibson Dunn. “Companies will need to carefully segregate their medical and adult-use operations if they want to benefit from 280E relief.”

The Adult-Use Question: What Happens Next?

The April 2026 order also initiated an expedited administrative hearing process, set to begin on June 29, 2026, that will consider whether to extend Schedule III classification to all forms of marijuana — including recreational or adult-use cannabis. This broader rescheduling question is far more politically charged and faces organized opposition from prohibitionist groups that have already signaled their intent to challenge the medical rescheduling in court.

“The hearing process is the real battleground,” said a policy analyst at the Rockefeller Institute of Government. “The medical rescheduling was the easy part — it had broad bipartisan support and aligned with the president’s campaign promises. But extending Schedule III to recreational cannabis means confronting the UN Single Convention on Narcotic Drugs, interstate commerce implications, and a more divided Congress.”

Legal observers note that the administration has created an interesting dynamic: medical cannabis patients and businesses now operate under a substantially normalized federal framework, while adult-use markets remain in their long-standing legal gray zone. This could accelerate the trend of states favoring medical programs over recreational frameworks, or alternatively, it could build momentum for full rescheduling as the practical benefits of Schedule III become evident.

Impact on Patients and Public Health

For the roughly 4 to 5 million Americans enrolled in state medical cannabis programs, rescheduling carries both symbolic and practical significance. Symbolically, it represents federal recognition that cannabis has legitimate medical applications — ending a half-century of official denial that contradicted the lived experience of millions of patients. Practically, it may improve access by reducing costs, enabling health savings account (HSA) and flexible spending account (FSA) reimbursement, and potentially paving the way for insurance coverage of FDA-approved cannabis medications.

Veterans, who have been among the most vocal advocates for rescheduling, stand to benefit particularly. The Department of Veterans Affairs has historically been unable to recommend or provide medical cannabis due to its Schedule I status, even as veterans reported using it to manage PTSD, chronic pain, and other service-connected conditions. Rescheduling opens the door for the VA to formally study and potentially integrate cannabis into veteran healthcare.

Public health experts, however, urge a balanced perspective. “Rescheduling is not deregulation,” cautioned one public health researcher. “Schedule III drugs are still controlled substances with prescribing and dispensing requirements. The goal should be to integrate cannabis into the healthcare system responsibly, with appropriate guardrails, evidence-based dosing guidelines, and monitoring for adverse effects — not to treat it like a dietary supplement.”

The order also addresses the broader cannabinoid market, tasking White House staff with working with Congress to update the statutory definition of hemp-derived cannabinoid products. A forthcoming ban on many consumer hemp products, effective November 12, 2026, will treat full-spectrum CBD products as marijuana under federal law — reversing aspects of the 2018 Farm Bill that had allowed the largely unregulated CBD market to explode.

Looking Ahead: A New Era for Cannabis Science and Policy

The rescheduling of medical cannabis to Schedule III marks the end of an era defined by prohibition-era science and the beginning of one grounded in evidence-based policy. Yet it is also, unmistakably, an incomplete reform. The exclusion of adult-use cannabis, the legal challenges ahead, and the looming administrative hearings all underscore that cannabis policy in America remains a work in progress.

For now, the most tangible effects will be felt in research laboratories finally free to study cannabis without the crushing weight of Schedule I restrictions, in medical cannabis businesses finally able to deduct ordinary business expenses, and among patients who can take some comfort in knowing that the federal government no longer officially insists their medicine has “no accepted medical use.”

“We’re witnessing the federal government slowly catching up to what patients and doctors have known for years,” said one advocate. “June 29 is the next milestone. That’s when we’ll find out whether this administration is prepared to go all the way.”

Medical Cannabis Rescheduled to Schedule III: A New Era for Research, Patients, and Policy最先出现在Health。